Cyclic peptides advance toward new drug targets, but manufacturing capacity may determine how fast

Cyclic peptides are gaining attention as a drug modality that could combine the selectivity of antibodies with some of the convenience and stability of small molecules.

Their ring-shaped structures can improve resistance to enzymatic breakdown, binding precision, and— in selected designs—oral absorption. They may also reach protein–protein interaction targets that conventional small molecules struggle to address.

The field still faces major technical hurdles:
reported oral bioavailability for many candidates remains below 1%, pharmacokinetic data are limited, and synthesis and purification can be fragile and difficult to scale.

Manufacturing is emerging as the key bottleneck. Cyclization, specialized purification, analytical controls, and limited GMP capacity make cyclic peptides more difficult to produce than conventional linear peptides.

Specialized contract manufacturers reportedly have long lead times—potentially 18–24 months—so developers may need to secure manufacturing partners during IND-enabling work rather than waiting for later clinical stages.

New approaches, including hybrid chemical and enzymatic synthesis, improved ADME/PK modeling, large-library screening, and AI-guided design, are being used to improve candidate selection and manufacturability.

The broader pipeline is expanding across oncology, autoimmune disease, infectious disease, metabolic disorders, and potentially central-nervous-system indications. However, the commercial opportunity will depend on whether manufacturing infrastructure can scale alongside discovery.